Retatrutide Vs Mounjaro: What Changes With A Third Receptor
Mounjaro hits two receptors. Ozempic hits one. Retatrutide hits three. That's why the hype is loud, and why the legal status matters.
Direct answer
Retatrutide is the investigational triple agonist. Mounjaro and Ozempic are approved medicines in Australia; retatrutide isn't.
Reviewed for
Drug-status distinction
Receptor comparison
Australian prescription boundary
Published 23 May 2026. Medical reviewer pending. No clinician credential is claimed.
Three receptors vs two vs one
Direct answer
Ozempic acts on GLP-1, Mounjaro acts on GLP-1 and GIP, and retatrutide acts on GLP-1, GIP, and glucagon.
Ozempic is semaglutide. It's a GLP-1 receptor agonist. Mounjaro is tirzepatide. It acts on GLP-1 and GIP. Retatrutide is described by Lilly as a triple hormone receptor agonist: GIP, GLP-1, and glucagon.
That's the reason retatrutide is being treated as the next wave instead of a copy.
Status in Australia
Direct answer
Mounjaro and Ozempic are approved Australian medicines. Retatrutide isn't.
Mounjaro and Ozempic are real Australian prescription medicines. Retatrutide isn't.
If someone presents retatrutide like a finished Australian pharmacy medicine today, that's the first warning sign.
What protects you matters
Direct answer
Prescription medicines need a practitioner pathway; peptide sellers need a batch path.
Prescription medicines need a practitioner pathway. Peptide sellers need a batch path.
For retatrutide, the checks are concrete: batch ID, COA, HPLC purity, Australian dispatch, payment protection, and support that answers.
Research peptides are not approved by the TGA for human use. Supplier links are for seller checks and buyer-protection review, not medical advice.
How we reviewed this article
This article was checked against primary source material, regulator pages, and the supplier-proof boundary used across this site. The goal is to keep retatrutide vs mounjaro: what changes with a third receptor useful without turning it into medical advice or a fake clinical recommendation.
Checked points
Drug-status distinction
Receptor comparison
Australian prescription boundary